Shots: Amathus to receive upfront and will be eligible for ~$500M milestones/program, if Merck exercise its option and will be responsible for identifying & progressing novel chaperone activators through preclinical discovery Merck to get an option to acquire Amathus Therapeutics along with its pipeline of mitochondrial targeted candidate to treat neurodegenerative disorders and renal diseases […]Read More
Shots: Yumanity will receive $500M upfront and milestones along with royalties on net sales of therapies, in exchange Merck to get an exclusive right to two novels Yumanity’s pipeline programs for the treatment of ALS and FTLD The collaboration integrates Yumanity’s drug discovery platform with Merck’s development and commercialization expertise in neuroscience Yumanity and […]Read More
Shots::stosohSthShots: Almac to receive upfront, research funding, development and commercial milestones along with the royalties on sales of products emerging from the collaboration. MSD will be responsible for conducting lead optimization, pre/clinical development and commercialization The collaboration will utilize Almac’s unique Ubi-Plex platform to identify and develop novel inhibitors against specified DUBs and will initially […]Read More
Shots: Pevail and Lonza to work collaboratively for process and analytical development plus large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston. Lonza to manufacture Prevail’s pipeline of novel AAV-based gene therapy programs for neurodegenerative diseases at its gene therapy center of excellence in Houston, TX […]Read More
Shots: Regenxbio and Neurimmune enter into a collaboration to develop vectorized Ab by combining antibodies identified using Neurimmune’s reverse translational medicine platform with Regenxbio’s NAV technology platform for chronic neuro-degenerative diseases including tauopathies The companies will jointly develop & commercialize AVV gene therapies with equal development cost-sharing with an initial focus on tauopathies. Following initial […]Read More
Shots: Skyhawk to receive upfront, milestones & royalties on sales and will discover & preclinically develop targeted therapies utilizing its SkySTAR technology. Takeda to get an exclusive WW license to develop & commercialize targeted therapies for multiple neurodegenerative diseases The focus of the agreement is to develop therapies directing central nervous system for improvement of […]Read More
Shots: Celgene to get non-exclusive rights for Aprinoia’s bAPN-1607 and Aprinoia to receive license and usage fee annually The focus of the agreement is utilize Aprinoia’s APN-1607 in developing therapies by understanding tau pathology in rare tauopathies including Alzheimer’s Disease APN-1607 is [18F]-labeled PET imaging tracer, enabling to visualize tau pathology in diverse tauopathies, MCI, […]Read More
Shots: AC Immune to receive $80M upfront, $1760M milestones and royalties on sales and Lilly to get WW commercialization rights for AC Immune’s tau aggregation inhibitors and will invest $50M as convertible notes in AC. AC to initiate P-I study for Morphomer inhibitors and Lilly to fund the trial The focus of the agreement is to develop AC Immune’s […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
